Correlation of pretreatment 18F-FDG uptake with clinicopathological factors and prognosis in patients with newly diagnosed diffuse large B-cell lymphoma
Honghui Huang(Creative Commons), Jianmin Wang(Changhai Hospital), Lan Xu(Creative Commons), Luying Zheng(Creative Commons), Jia Liu(Chinese Academy of Sciences), Jianyi Zhu(Creative Commons), Yi Fang(Changsha Central Hospital), Jianjun Liu(Amsterdam UMC Location Vrije Universiteit Amsterdam), Qiang Liu(China Agricultural University), Xiaofeng Han(Creative Commons), Fangyuan Chen(Renji Hospital), Fei Xiao(Creative Commons), Lu Zhong(Renji Hospital), Yumei Chen(Zhengzhou University), Yiping Shi(Creative Commons), Minyue Zhang(Creative Commons), Lijing Shen(Creative Commons), Beiwen Ni(Creative Commons), Ting Wang(Washington University in St. Louis), Hua Zhong(Creative Commons)
Cited by 21
Related Papers
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
|New England Journal of Medicine|2022|2.5k
Large-scale genotyping identifies 41 new loci associated with breast cancer risk
|Nature Genetics|2013|1.1k
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer
|Annals of Oncology|2021|724
Associations of Breast Cancer Risk Factors With Tumor Subtypes: A Pooled Analysis From the Breast Cancer Association Consortium Studies
|JNCI Journal of the National Cancer Institute|2010|716